Treatment of essential hypertension. Dafiro is indicated in patients whose blood pressure is not adequately controlled on amlodipine or valsartan monotherapy.
AMLODIPINE AND VALSARTAN — STRIDES PHARMA INTL, approved 2016-02-05 (ANDA090011).
160,115 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.